Forkhead box A1 (FOXA1) is a pioneer transcription factor that is essential for the normal development of several endoderm-derived organs, including the prostate gland 1, 2 . FOXA1 is frequently mutated in hormone-receptor-driven prostate, breast, bladder and salivarygland tumours [3] [4] [5] [6] [7] [8] . However, it is unclear how FOXA1 alterations affect the development of cancer, and FOXA1 has previously been ascribed both tumour-suppressive 9-11 and oncogenic 12-14 roles. Here we assemble an aggregate cohort of 1,546 prostate cancers and show that FOXA1 alterations fall into three structural classes that diverge in clinical incidence and genetic co-alteration profiles, with a collective prevalence of 35%. Class-1 activating mutations originate in early prostate cancer without alterations in ETS or SPOP, selectively recur within the wing-2 region of the DNA-binding forkhead domain, enable enhanced chromatin mobility and binding frequency, and strongly transactivate a luminal androgen-receptor program of prostate oncogenesis. By contrast, class-2 activating mutations are acquired in metastatic prostate cancers, truncate the C-terminal domain of FOXA1, enable dominant chromatin binding by increasing DNA affinity and-through TLE3 inactivationpromote metastasis driven by the WNT pathway. Finally, class-3 genomic rearrangements are enriched in metastatic prostate cancers, consist of duplications and translocations within the FOXA1 locus, and structurally reposition a conserved regulatory element-herein denoted FOXA1 mastermind (FOXMIND)-to drive overexpression of FOXA1 or other oncogenes. Our study reaffirms the central role of FOXA1 in mediating oncogenesis driven by the androgen receptor, and provides mechanistic insights into how the classes of FOXA1 alteration promote the initiation and/or metastatic progression of prostate cancer. These results have direct implications for understanding the pathobiology of other hormone-receptor-driven cancers and rationalize the co-targeting of FOXA1 activity in therapeutic strategies.
To study these alterations, we first curated an aggregate cohort of prostate cancer that comprised 888 localized and 658 metastatic samples 4, 5, 8, 20 , of which 498 and 357, respectively, had matched RNAsequencing (RNA-seq) data. Here, FOXA1 mutations recurred at a frequency of 8-9% in primary disease, which increased to 12-13% in metastatic castration-resistant prostate cancer (mCRPC) (Fig. 1a , Extended Data Fig. 1j ). RNA-seq calls of structural variants revealed a high prevalence (Fig. 1b , Supplementary Table 1 ) and density (Extended Data Fig. 1k ) of rearrangements within the FOXA1 locus. The presence of structural variants was confirmed by whole-exome and wholegenome sequencing (Extended Data Fig. 1l , m, Supplementary Tables 2, 3) . Overall, we estimated the recurrence of FOXA1 locus rearrangements to be 20-30% in mCRPC (Extended Data Fig. 1n ). All FOXA1 mutations were heterozygous and FOXA1 itself was copy-amplified in over 50% of cases with no biallelic deletions (Extended Data Fig. 2a, b) . We also found a stagewise increase in FOXA1 expression in prostate cancer (Extended Data Fig. 2c , Supplementary Discussion).
When we mapped mutations onto the protein domains of FOXA1, we found two structural patterns: (1) missense and in-frame insertion and deletion (indel) mutations were clustered at the C-terminal end of the forkhead domain (FKHD); and (2) truncating frameshift mutations were restricted to the C-terminal half of the protein (Fig. 1c) . FOXA1 structural variants predominantly consisted of tandem duplications and translocations, which clustered in close proximity to the FOXA1 gene without disrupting its coding sequence (Fig. 1d) . Thus, we categorized FOXA1 alterations into three structural classes: class 1, which comprises all the mutations within the FKHD; class 2, which comprises mutations in the C-terminal end after the FKHD; and class 3, which comprises structural variants within the FOXA1 locus (Fig. 1c,  d , Extended Data Fig. 2d ). We also found similar classes of FOXA1 alterations in breast cancer (Extended Data Fig. 2e, f) .
We found that the majority of FOXA1 mutations in primary prostate cancer belonged to class 1, which showed no enrichment in the metastatic disease (Fig. 1e) . Conversely, class-2 mutations were significantly enriched in metastatic prostate cancer; in the rare primary cases with class-2 mutations, the mutant allele was detected at sub-clonal frequencies (Fig. 1e , f, Extended Data Fig. 2g, h ). We found no cases that possessed both class-1 and class-2 mutations. Class-3 structural variants were also significantly enriched in mCRPC (odds ratio = 3.46) (Fig. 1g) . Overall, we found the cumulative frequency of FOXA1 alterations to be over 34% in mCRPC (Fig. 1h) . Assessment of concurrent alterations revealed that class-1 mutations are mutually exclusive with other primary events (for example, ETS fusions) (odds ratio = 0.078), whereas class-2-mutant mCRPC are enriched for RB1 deletions (odds ratio = 4.17) (Extended Data Fig. 2i, j) . Both mutational classes were further enriched for alterations in DNA repair, mismatch repair and
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WNT signalling pathways (Extended Data Fig. 2i , k), and had higher levels of expression of FOXA1 mRNA relative to the wild-type cases (Extended Data Fig. 2l ). Together, these data suggest that class-1 mutations emerge in localized prostate cancer, whereas class-2 and class-3 mutations are acquired or enriched, respectively, in the course of disease progression.
Class-1 mutations consist of missense and in-frame indels that cluster at the C-terminal edge of the winged-helix DNA-binding FKHD. The majority of the class-1 mutations were located either within the wing-2 region (residues 247-269) or a 3D hotspot that spatially protrudes towards wing 2 21 ( Fig. 2a, b , Extended Data Fig. 3a, b) . Notably, these mutations did not alter FKHD residues that make basespecific interactions with the DNA 22, 23 (Fig. 2a , Extended Data Fig. 3c ). In FOXA proteins, wing-2 residues make base-independent (that is, non-specific) contacts with the DNA backbone 23, 24 that reportedly impede its nuclear movement 24 . Thus, we hypothesized that class-1 mutants with altered wing-2 regions would display faster nuclear mobility.
We cloned representative class-1 mutants of FOXA1: I176M (mutation of the 3D hotspot), R261G (missense) and R265-Q271del (in-frame deletion), all of which retained nuclear localization (Extended Data Fig. 3d ). In fluorescence recovery after photobleaching (FRAP) assays, we found class-1 mutants had 5-6× faster nuclear mobility irrespective of the mutation type (Fig. 2c, d , Extended Data Fig. 3e, g ). By contrast, class-2 mutants with intact wing-2 regions were sluggish in their nuclear movement (Fig. 2d, Extended Data Fig. 3f, g ). Using single particle tracking, we verified that class-1 mutants have a higher overall rate of nuclear diffusion, with 3-4-fold fewer slow particles and shorter chromatin dwell times (Extended Data Fig. 3h, i) . In chromatin immunoprecipitation with parallel DNA sequencing (ChIP-seq) assays, we found that ectopically expressed class-1 mutants in HEK293 cells bind DNA at the consensus FOXA1 motif (Extended Data Fig. 3j, k) . In prostate cancer cells, the class-1 cistrome entirely overlapped with wild-type binding sites, with similar enrichment for FOXA1 and AR cofactor motifs, AR-binding sites and genomic distribution (Extended Data Fig. 3l-s) . Furthermore, in growth rescue experiments using untranslated-region-specific small interfering (si) RNAs that targeted the endogenous FOXA1 transcript, we found that exogenous class-1 mutants fully compensated for the wild-type protein (Extended Data Fig. 4a ).
Next, we asked how class-1 mutations affect AR signalling. Similar to wild-type FOXA1, both class-1 and class-2 mutants interacted with the AR signalling complex (Extended Data Fig. 4b-d) . In reporter assays, class-1 mutants induced 3-6-fold higher activation of AR signalling (Fig. 2e) , which was evident even under stimulation with castrate levels of androgen or treatment with enzalutamide (Extended Data Fig. 4e, f) . In parallel assays, class-2 mutants showed no differences relative to wild-type FOXA1 (Fig. 2e) . Transcriptomic analyses of class-1 tumours from patients revealed the activation of hyperproliferative and protumorigenesis pathways, and further enrichment of primary prostate cancer genes (Extended Data Fig. 4g-i) . Notably, AR was predicted 25 to be the driver transcription factor for class-1 upregulated genes, which we experimentally confirmed for several targets (Extended Data Fig. 4j-l) . Concordantly, overexpression of class-1 mutants in 22RV1 cells increased growth in androgen-depleted medium (Fig. 2f) but not in androgen-supplemented medium, and rescued proliferation upon treatment with enzalutamide (Extended Data Fig. 4m , n). For class-1 downregulated genes, the basal transcription factors TP63 and SOX2 were predicted to be transcriptional drivers (Extended Data Fig. 4j ). Consistently, in class-1 specimens from patients, both of these transcription factors were significantly downregulated, with a concomitant downregulation of basal, and upregulation of luminal, markers (Fig. 2g , Extended Data Fig. 4o, p) . In addition, class-1 tumours had a higher AR transcriptional signature, and a lower neuroendocrine transcriptional signature (Extended Data Fig. 4q ). Together, these data suggest that class-1 mutations that alter the wing-2 region increase the nuclear speed and genome-scanning efficiency of FOXA1 without affecting its DNA sequence specificity (Supplementary Discussion), and drive a luminal AR program of prostate oncogenesis (Fig. 2h) . Class-2 mutations consist of frameshifting alterations that truncate the C-terminal regulatory domain of FOXA1 (Fig. 3a) . Thus, we characterized the class-2 cistrome by using N-terminal and C-terminal antibodies, with the C-terminal antibody binding exclusively to wildtype FOXA1 (Extended Data Fig. 5a, b) . Notably, mCRPC-derived LAPC4 cells endogenously contained a FOXA1 class-2 mutation (that is, a frameshift at amino acid P358 (P358fs)), and both wildtype and mutant variants interacted with the AR complex (Extended Data Fig. 5c-f) . However, in ChIP-seq assays, only the N-terminal antibody detected FOXA1 binding to the DNA. By contrast, N-terminal and C-terminal FOXA1 cistromes substantially overlapped in wild-type prostate cancer cells (Fig. 3b, Extended Data Fig. 5g-i) . Even with 13-fold overexpression of wild-type FOXA1 in LAPC4 cells, the endogenous class-2 mutant retained its binding dominance (Fig. 3b, Extended Data Fig. 5j, k) . Conversely, overexpression of the FOXA1(P358fs) mutant in LNCaP cells markedly diminished the endogenous wild-type cistrome (Fig. 3b) . In in vitro assays, class-2 mutants showed markedly stronger binding to the KLK3 enhancer element (Fig. 3c, Extended Data Fig. 6a-d) , and biolayer interferometry confirmed that the FOXA1(P358fs) mutant has an approximately fivefold-higher DNA-binding affinity (Extended Data Fig. 6e ). In CRISPR-engineered class-2-mutant 22RV1 clones (Extended Data  Fig. 6f, g ), FOXA1 ChIP-seq data reaffirmed the cistromic dominance of class-2 mutants (Fig. 3d) . Knockdown of either mutant FOXA1 or AR in 22RV1 or LNCaP class-2 CRISPR clones significantly attenuated proliferation (Fig. 3e, Extended Data Fig. 6h, i) . Consistently, in rescue experiments, the FOXA1(P358fs) mutant fully compensated for the loss of wild-type FOXA1 (Extended Data Fig. 4a ).
The class-2 cistrome was considerably larger than the wild-type cistrome (Extended Data Fig. 6j-l) , and the acquired sites were enriched for the CTCF motif and distal regulatory regions (Extended Data Fig. 7a-e, Supplementary Discussion) . In transcriptomic and motif analyses of the class-2 clones, LEF and TCF were predicted as a   FOXA1   HAKPPYS-YISLITMAIQQ-APS-KMLT-LSEIYQWIMDLF-PYYRQNQQ-RWQNSIRHSLSF-NDC-FVKV-ARSPDKPGKGS-YWTL-HPDSGNMF ENGCYLRRQKRFKCE   H1  S1  H2  H3  S2  S3  Wing 2  W1  Amino  acid 168  269  247   50 100 150 200 250 300 350 400 450   TD  RD  FKHD W2   247   0   2   4   6   8   10   12 Missense
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FKHD structure
Base-speci c DNA-contacting residues Amino acid b, Crystal structure of the FKHD with visualization of non-wing-2 (that is, outside of amino acids 247-269) mutations. Mutations in the 3D hotspot are in red. c, FRAP kinetic plots (left) and representative time-lapse images from pre-bleaching to the equilibrated state (right; n = 6 biological replicates). Images are uniformly brightened for signal visualization. WT, wild type. d, FRAP durations until 50% recovery (n = 6 nuclei per variant). e, Negative control (NC) or AR reporter (rep) activity with overexpression of FOXA1 variants and dihydrotestosterone (DHT) stimulation (n = 3 biological replicates). f, Growth (IncuCyte) of 22RV1 cells that overexpress FOXA1 variants in androgen-depleted medium (n = 5 biological replicates). In d-f, mean ± s.e.m. is shown, and P values are from two-way analysis of variance (ANOVA) and Tukey's test. g, Relative expression of luminal and basal markers in class-1 (n = 38) tumours compared with wild-type (n = 457), SPOP (n = 48) and ETS (n = 243) primary prostate cancer tumours. h, Class-1 model. Wing-2-disrupted FOXA1 shows increased chromatin mobility and chromatin sampling frequency, which results in stronger transcriptional activation of oncogenic AR signalling. FKRE, forkhead-responsive element; ARE, androgen-responsive element.
Letter reSeArCH the top regulatory transcription factors for the upregulated genes (Extended Data Fig. 7g, h ). The LEF-TCF complex is the primary nuclear effector of WNT signalling and remains inactive until it is bound by β-catenin 26 . Consistently, we found a marked accumulation of transcriptionally active β-catenin-that is, non-phosphorylated at S31, S37 and T41-in distinct mutant clones, as well as a concomitant increase in the expression of the WNT targets LEF1 and AXIN2 (Extended Data Fig. 7i, j) . Class-2 clones showed 2-3-fold higher invasiveness in Boyden chamber assays (Extended Data Fig. 7k, l) , and a higher rate and extent of metastatic dissemination in zebrafish embryos (Fig. 3f, Extended Data Fig. 7m ). In these assays, class-1 mutant cells showed no differences relative to wild-type cells (Extended Data  Fig. 7n ). Furthermore, treatment with the WNT inhibitor XAV939 completely abrogated the class-2 invasive phenotype (Extended Data  Fig. 7o ). Investigating the mechanism that underlies this invasiveness, we found that FOXA1 transcriptionally activates and-through its C-terminal domain-recruits TLE3 (a bona fide WNT co-repressor 27 ) to the chromatin (Extended Data Fig. 8a-e) . Class-2 mutants had lost this interaction, which led to the untethering of TLE3 from chromatin and downstream activation of WNT signalling (Fig. 3g , h, Extended Data Fig. 8e-k, Supplementary Discussion) . Together, these data suggest that class-2 mutations confer cistromic dominance and abolish TLE3-mediated repression of the WNT program of metastasis (Fig. 3i) .
Class-3 rearrangements occur within the PAX9 and FOXA1 locus that is linearly conserved across the deuterostome superphylum 28 (Fig. 4a) . Notably, almost all break ends were clustered within the FOXA1 topologically associating domain (Extended Data Fig. 9a ). We found that the genes located within the FOXA1 topologically associating domain had the highest expression in the normal prostate, and the non-coding RP11-356O9.1 transcript had a prostate-specific expression (Extended Data Fig. 9b ). Furthermore, in patient tumours, expression of RP11-356O9.1 was strongly correlated with FOXA1 and TTC6 expression (Extended Data Fig. 9c) . Thus, to identify prostate-specific enhancers of the FOXA1 topologically associating domain, we performed the assay for transposase-accessible chromatin using sequencing (ATACseq) and interrogated chromatin features in AR + and AR − prostate cells. Notably, a CTCF-bound intronic site in RP11-356O9.1 (hereafter denoted as FOXMIND) and a site within the 3′ untranslated region of MIPOL1 were accessible and marked with active enhancer modifications only in AR +
FOXA1
+ prostate cancer cells (Fig. 4b, Extended Data  Fig. 9d ). This strongly suggested that these conserved sites function as enhancer elements. Consistently, CRISPR knockout of these loci in VCaP cells led to a significant decrease in the expression of FOXA1 and TTC6-but not of MIPOL1, which has its promoter outside of the FOXA1 topologically associating domain (Extended Data Fig. 9d, e) .
We found that translocations were largely within a 50-kb region between FOXA1 and the 3′ untranslated region of MIPOL1, whereas break-end junctions from duplications mostly flanked the FOXMIND-FOXA1 region (Fig. 4a, Extended Data Fig. 9f ). For translocations, we delineated two patterns: (1) the hijacking of the FOXMIND enhancer; and (2) insertions upstream of the FOXA1 promoter (Fig. 4c) . The first pattern subsumes previously reported in-frame fusion genes that involve RP11-356O9.1, ETV1 29 and SKIL
30
, as well as a newly reported ASXL1 fusion (Supplementary Table 4 ). The second pattern inserts an oncogene (such as CCNA1) upstream of FOXA1 (Fig. 4c) . Notably, both mechanisms resulted in outlier expression of the translocated gene (Extended Data Fig. 9g ). For duplications, which constitute 70% of all rearranged cases, we found FOXMIND and FOXA1 to be co-amplified in 89% of the rearranged cases and never separated (Fig. 4c , bottom, Extended Data Fig. 9h) , thus preserving the FOXMIND-FOXA1 regulatory domain.
Next, while assessing the transcriptional effect of duplications, we found that levels of FOXA1 mRNA were poorly correlated with copy number (Extended Data Fig. 10a ), but highly sensitive to focal structural variants. Tandem duplications (ascertained at the RNA and DNA levels) significantly increased expression of FOXA1 and MIPOL1, but not of TTC6 (Fig. 4d) . Translocations resulted in a modest decrease in expression levels of FOXA1 (Extended Data Fig. 10b) , despite a significant co-occurrence with tandem duplications (odds ratio = 3.89, Extended Data Fig. 10c ). To investigate this further, we carried out haplotype-resolved, linked-read sequencing of MDA-PCA-2b cells, which contain a translocation of FOXMIND and ETV1. Here, ETV1 translocation was accompanied by a focal tandem duplication in the non-translocated FOXA1 allele (Extended Data Fig. 10d ). The translocated FOXA1 allele was inactivated, which resulted in monoallelic transcription (Extended Data Fig. 10e ) without a net loss in FOXA1 expression (266 fragments per kilobase of transcript per million mapped reads, 95th percentile in mCRPC). By contrast, RP11-356O9.1 retained biallelic expression (Extended Data Fig. 10f ). In LNCaP cells, which also contain an ETV1 translocation into the FOXA1 locus, deletion of FOXMIND caused a significant reduction in ETV1 expression (Extended Data Fig. 10g) . Thus, translocations result in the loss of FOXA1 expression from the allele in cis, which is rescued by tandem duplications of the allele in trans. Altogether, we propose a coalescent model in which class-3 structural variants duplicate or reposition 
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FOXMIND to drive overexpression of FOXA1 or other oncogenes (Fig. 4e) .
In summary, we identify three structural classes of FOXA1 alterations that differ in genetic associations and oncogenic mechanisms. We establish FOXA1 as a principal oncogene in AR-dependent prostate cancer that is altered in 34.6% of mCRPC. Given the unique pathogenic features of the three classes, we have named them the 'FAST' (class-1), 'FURIOUS' (class-2) and 'LOUD' (class-3) alterations of FOXA1 (Figs. 2h, 3i, 4e, Supplementary Table 5 , Supplementary Discussion). Structurally equivalent FOXA1 alterations are also found in other hormone-receptor-driven cancers, thus positioning FOXA1 as a promising target for therapeutic strategies in these malignancies.
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METHODS
Cell culture. Most cell lines were originally purchased from the American Type Culture Collection (ATCC) and were cultured as per standard ATCC protocols. LNCaP-AR and LAPC4 cells were gifts from the laboratory of C. Sawyers (Memorial Sloan Kettering Cancer Center). Unless otherwise stated, for all the experiments LNCaP, PNT2, LNCaP-AR, C42B, 22RV1, DU145 and PC3 cells were grown in the RPMI 1640 medium (Gibco) and VCaP cells in the DMEM with Glutamax (Gibco) medium supplemented with 10% full bovine serum (FBS; Invitrogen). LAPC4 cells were grown in IMEM (Gibco) supplemented with 15% FBS and 1 nM of R1881. For the immortalized normal prostate cells: RWPE1 cells were grown in keratinocyte medium with regular supplements (Lonza); PNT2 cells were grown in RPMI medium with 10% FBS. HEK293 cells were grown in DMEM (Gibco) medium with 10% FBS. All cells were grown in a humidified 5% CO 2 incubator at 37 °C. All cell lines were tested once a fortnight to be free of mycoplasma contamination and genotyped every month at the University of Michigan Sequencing Core using Profiler Plus (Applied Biosystems) and compared with corresponding short tandem repeat profiles in the ATCC database to authenticate their identity in culture between passages and experiments. Antibodies. For immunoblotting, the following antibodies were used: Immunoblotting and nuclear co-immunoprecipitation. Cell lysates were prepared using the RIPA lysis buffer (Thermo Fisher Scientific; cat. no. 89900) and denatured in the complete NuPage 1× LDS/reducing agent buffer (Invitrogen) with 10 min heating at 70 °C. Between 10 and 25 μg of total protein was loaded per well, separated on 4-12% SDS polyacrylamide gels (Novex) and transferred onto 0.45-μm nitrocellulose membrane (Thermo Fisher Scientific; cat. no. 88018) using a semi-dry transfer system (Trans-blot Turbo System; BioRad) at 25 V for 1 h. The membrane was incubated for 1 h in blocking buffer (Tris-buffered saline, 0.1% Tween (TBS-T), 5% non-fat dry milk) and incubated overnight at 4 °C with primary antibodies. When samples were run on multiple gels for an experiment, multiple loading control proteins (GAPDH, β-actin, total H3 and vinculin) were probed on each membrane separately. Host-species-matched secondary antibodies conjugated to horseradish peroxidase (HRP; BioRad) were used at 1/20,000 dilution to detect primary antibodies and blots were developed using enhanced chemiluminescence (ECL Prime, Thermo Fisher Scientific) following the manufacturer's protocol.
For nuclear co-immunoprecipitation assays, 8-10 million cells ectopically overexpressing different V5-tagged FOXA1 variants and wild-type AR (or TLE3) were fractionated to isolate intact nuclei using the NE-PER kit reagents (Thermo Fisher Scientific; cat. no. 78835) and lysed in the complete IP lysis buffer (Thermo Fisher Scientific; cat. no. 87788). Nuclear lysates were incubated for 2 h at 4 °C with 30 μl of magnetic protein-G Dynabeads (Thermo Fisher Scientific; cat. no. 10004D) for pre-clearing. A fraction of the pre-cleared lysate was saved as input and the remainder was incubated overnight (12-16 h) with 10 μg of target protein antibody at 4 °C with gentle mixing. Next day, 50 μl of Dynabeads protein-G beads were added to the lysate-antibody mixture and incubated for 2 h at 4 °C. Beads were washed three times with IP buffer (150 nM NaCl; Thermo Fisher Scientific) and directly boiled in 1× NuPage LDS/reducing agent buffer (ThermoFisher Scientific; cat. no. NP0007 and NP0009) to elute and denature the precipitated proteins. These samples were then immunoblotted as described above with the exception of using protein A-HRP secondary (GE HealthCare; cat. no. NA9120-1ML) antibody for detection. RNA extraction and quantitative polymerase chain reaction. Total RNA was extracted using the the miRNeasy Mini Kit (Qaigen), with the inclusion of the on-column genomic DNA digestion step using the RNase-free DNase Kit (Qaigen), following the standard protocols. RNA was quantified using the NanoDrop 2000 Spectrophotometer (ThermoFisher Scientific) and 1 μg of total RNA was used for complementary DNA (cDNA) synthesis using the SuperScript III Reverse Transcriptase enzyme (Thermo Fisher Scientific) following the manufacturer's instructions. Twenty nanograms of cDNA was input per polymerase chain reaction (PCR) using the FAST SYBR Green Universal Master Mix (Thermo Fisher Scientific) and every sample was quantified in triplicate. Gene expression was calculated relative to GAPDH and HPRT1 (loading control) using the ΔΔC t method and normalized to the control group for graphing. Quantitative PCR (qPCR) primers were designed using the Primer3Plus tool (http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi) and synthesized by Integrated DNA Technologies.
Primer used in this study are listed below: GAPDH: forward (F), TGCACCACCA ACTGCTTAGC and reverse (R), GGCATGGACTGTGGTCATGAG; HPRT1: F, AGGCGAACCTCTCGGCTTTC and R, CTAATCACGACGCCAGGGCT; ACTB: F, AGGATGCAGAAGGAGATCACTG and R, AGTACTTGCGCTCAGGAGGAG; AR: F, CAGTGGATGGGCTGAAAAAT and R, GGAGCTTGGTGAGCTGGTAG; FOXA1-3′: F, GAAGACTCCAGCCTCCTCAACTG and R, TGCCTTGAAGTCCA GCTTATGC; FOXA1-5′: F, CTACTACGCAGACACGCAGG and R, CCGCTCGTAGTCATGGTGTT; TLE3: F, AAGGACAGCTTGAGCCGATA and R, TTTGGTCTTGGAGGAAGGTG; TTC6: F, CGAACAGAGCCAGGAGGT AG and R, GTTCTCCCTGGGCTCCTAAC; MIPOL1: F, GCAAACGGTTAGAGC AGGAG and R, GGGTCTGGATTTCCTCTTCC; ETV1: F, TACCCCATGGACC ACAGATT and R, CACTGGGTCGTGGTACTCCT; TUBB: F,CTGGACCGCATC TCTGTGTACT and R,GCCAAAAGGACCTGAGCGAACA. siRNA-mediated gene knockdown. Cells were seeded in a 6-well plate at the density of 100,000-250,000 cells per well. After 12 h, cells were transfected with 25 nM of gene-targeting ON-TARGETplus SMARTpool siRNAs or nontargeting pool siRNAs as negative control (Dharmacon) using the RNAiMAX reagent (Life Technologies; cat. no. 13778075) on two consecutive days, following the manufacturer's instructions. Both total RNA and protein were extracted on day 3 (total 72 h) to confirm efficient (>80%) knockdown of the target genes. For crystal-violet staining, at day 9 growth medium was aspirated and cells were first fixed with 4% formaldehyde solution, followed by a 30-min incubation in 0.5% crystal-violet solution in 20% methanol, and then scanned. Catalogue numbers and guide sequences (5′ to 3′) of siRNA SMARTpools (Dharmacon) used are: non-targeting control (cat. no. D-001810-10-05; UGGUUUACAUGUCGACUAA, UGGUUUACAUGUUGUGUGA, UGGUUUACAUGUUUUCUGA, UGGUUUA CAUGUUUUCCUA); AR (cat. no. L-003400-00-0005; GAGCGUGGACUUUCCG GAA, UCAAGGAACUCGAUCGUAU, CGAGAGAGCUGCAUCAGUU, CAGAAAUGAUUGCACUAUU); FOXA1 (cat. no. L-010319-00-0005; GCACUGCAAUACUCGCCUU, CCUCGGAGCAGCAGCAUAA, GAACAGCU ACUACGCAGAC, CCUAAACACUUCCUAGCUC); TLE3 (cat. no. L-019929-00-0005; GCCAUUAUGUGAUGUACUA, GCAUGGACCCGAUAGGUAU, GAACCACCAUGAACUCGAU, UCAGGUCGAUGCCGGGUAA).
The FOXA1 SMARTpool consists of siRNAs targeting 5′ as well as 3′ ends of the FOXA1 transcript. Thus, both wild-type and class-2 mutant transcripts are degraded using the SMARTpool siRNAs. This was experimentally confirmed in LAPC4 cells that endogenously contain a FOXA1 class-2 mutation (Extended Data  Fig. 1d, e) . CRISPR-Cas9-mediated gene or enhancer knockout. Cells were seeded in a 6-well plate at the density of 200,000-300,000 cells per well and infected with viral particles with lentiCRISPR-V2 plasmids coding either non-targeting (sgNC) or single guide RNAs (sgRNAs) targeting the exon 1 or the FKHD of FOXA1 (both resulting in FOXA1 inactivation). This was followed by three days of puromycin selection, after which proliferation assays were carried out as described below. The lentiCRISPR-V2 vector was a gift from the laboratory of F. Zhang (Addgene plasmid no. 52961).
sgRNA sequences used are as follows: sgNC no. 1: 5′-GTAGCGAACGTGTCC GGCGT-3′; sgNC no. 2: 5′-GACCGGAACGATCTCGCGTA-3′; sgFOXA1 exon 1: 5′-GTAGTAGCTGT TCCAGTCGC-3′; sgFOXA1 FKHD: 5′-GCCGTTCTCGAACATGTTGC-3′.
Alternatively, for functional interrogation of the FOXA1 topologically associating domain (TAD) enhancer elements, VCaP or LNCaP cells were transfected with pairs of sgRNAs targeting the MIPOL1 untranslated region (UTR) or FOXMIND or a control locus within the FOXA1 TAD. Transfected cells were then selected with puromycin (1.0 μg/ml) for 48 h, followed by incubation for an additional 72 h. Total RNA was extracted and qPCR was performed as described above.
Pairwise sgRNA sequences are as follows (5′ to 3′): control sgRNA (sgCtrl): CA CCGATTAGCCTCAACTATACCA and CACCGTGCAATATCTGAATCACACG; sgMIPOL1 UTR: CACCGTGAAAAAAAACGACAGTCTG and CACCGAACTC AAGTCAGCAGCAAAG; sgFOXMIND 1: CACCGCTTTAATAAAGCTATTTGC and CACCGATAGAGTGACTAATGCCCTG; sgFOXMIND 2: CACCGTAACAGT TGACCTACTAAC and CACCGATTTAGATAAGGGGATAGAA; sgFOX-MIND 3: CACCGCTTTAATAAAGCTATTTGC and CACCGATTTAG ATAAGGGGATAGAA. CRISPR knockout screen. For the genome-wide CRISPR knockout screen, a two-vector system was used. First, LNCaP cells were engineered to stably overexpress the enzymatically active Cas9 protein. These cells were then treated with the human GeCKO knockout sgRNA library (GecKO V2) that was a gift from the Zhang laboratory (Addgene; cat. no. 1000000049). This was followed by puromycin Letter reSeArCH selection for 48 h, after which a fraction of these cells was processed to isolated genomic DNA as the input sample. The remaining cells were then cultured for 30 days, and genomic DNA was extracted at this time point. sgRNA sequences were amplified using common adaptor primers and sequenced on the Illumina HiSeq 2500 (125-nucleotide read length). Sequencing data were analysed as described 31 and depletion or enrichment of individual sgRNAs at 30 days was calculated relative to the input sample. Note that only a subset of genes-including essential controls, epigenetic regulators and transcription factors from the GeCKO-V2 screen-was plotted in Extended Data Fig. 1i . Proliferation assays. For siRNA growth assays, cells were directly plated in a 96-well plate at the density of 2,500-8,000 cells per well and transfected with gene-specific or non-targeting siRNAs, as described above, on day 0 and day 1. Every treatment was carried out in six independent replicate wells. CellTiter-Glo reagent (Promega) was used to assess cell viability at multiple time points after tranfection, following the manufacturer's protocol. Data were normalized to readings from siNC treatment on day 1, and plotted as relative cell viability to generate growth curves.
Alternatively, for CRISPR sgRNA growth assays, cells were treated as described above for target-gene inactivation and seeded into a 24-well plate at 20,000 cells per well, with 2 replicates per group. After 12 h, plates were placed into the IncuCyte live-cell imaging machine (IncuCyte) set at the phase-contrast option to record cell confluence every 3 h for between 7 and 9 days. Similarly, for class-1 growth assays (Fig. 2f) , stable doxycycline-inducible 22RV1 cells were grown in 10% charcoalstripped-serum (CSS)-supplemented medium for 48 h. Androgen-starved cells were then seeded into a 96-well plate at 5,000 cells per well in 10% CSS medium with or without addition of doxycycline (1 μg/ml) to induce control or mutant protein expression (6 replicates per group). Once adherent, treated cells were placed in the IncuCyte live-cell imaging machine set at phase contrast to record cell confluence every 3 h for between 7 and 9 days. In all IncuCyte assays, confluence measurements from all time points were normalized to the matched measurement at 0 h and plotted as relative confluence to generate growth curves. Cloning of representative FOXA1 mutants. Wild-type FOXA1 coding sequence was purchased from Origene (cat. no. SC108256) and cloned into the pLenti6/V5 lentiviral vector (Thermo Fisher Scientific; cat. no. K4955-10) using the standard TOPO cloning protocol. Class-1 missense mutations (I176M, H247Q and R261G) were engineered from the wild-type FOXA1 vector using the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Tech) as per the manufacturer's instructions. All point mutations were confirmed using Sanger sequencing through the University of Michigan Sequencing Core Facility. Engineered mutant plasmids were further transfected in HEK293 cells to confirm expression of the mutant protein. For truncated class-2 variants, the wild-type coding sequence up to the amino acid before the intended mutation was cloned. All FOXA1 variants had the V5 tag fused on the C terminus. Selected mutants were cloned into a doxycycline-inducible vector (Addgene: pCW57.1; cat. no. 41393) to generate stable lines. For FRAP and single particle tracking assays, the pCW57.1 vector was edited to incorporate an in-frame GFP or Halo coding sequences at the C-terminal end, respectively. FRAP assay and data quantification. PNT2 cells were seeded in a 6-well plate at 200,000 cells per well, and transfected with 2 μg of doxycycline-inducible vectors that encoded different variants of FOXA1 fused to GFP on the C-terminal end. After 24 h, cells were plated in glass-bottom microwell dishes (MatTek; #P35G-1.5-14-C) in phenol-free growth medium supplemented with doxycycline (1 μg/ml). Cells were then incubated for 48 h to allow for robust expression of the exogenous GFP-tagged protein and strong adherence to the glass surface. Microwell dishes were placed in humidity-controlled chamber set at 37 °C (TokaiHit) and mounted on the SP5 Inverted 2-Photon FLIM Confocal microscope (Leica). FRAP Wizard from the Leica Microsystems software suite was used to conduct and analyse FRAP experiments. Fluorescence signals were automatically computed in regions of interest using in-built tools in the FRAP Wizard. Roughly half of the nucleus was photobleached using the argon laser at 488 nm and 100% intensity for 20-30 iterative frames at 1.2-s intervals. Laser intensity was reduced to 1% for imaging post bleaching. Immediately after photobleaching, 2 consecutive images were collected at 1.2-s intervals followed by images taken at 10-s intervals for 60 frames (that is, 10 min).
For data analyses, recovery of signal in the bleached half and loss of signal in the unbleached half were measured as average fluorescence intensities in at least 80% of the respective areas, excluding the immediate regions flanking the separating border. All intensity curves were generated from background-subtracted images. The fluorescence signal measured in a region of interest was normalized to the signal before bleaching using the following formula 32 : R = (I t − I bg )/(I o − I bg ), in which I o is the average intensity in the region of interest before bleaching, I t is the average intensity in the region of interest at any time-point after bleaching and I bg is the background fluorescence signal in a region outside of the cell nucleus. Raw recovery kinetic data from above were fitted with best hyperbolic curves using the GraphPad Prism software and the time until 50% recovery was calculated from the resulting best-fit equations. For representative time-lapse nuclei images shown in the FRAP figures, the fluorescence signal was uniformly brightened for ease of visualization. Single particle tracking experiment and data quantification. PNT2 cells were transiently transfected with doxycycline-inducible vectors encoding C-terminal Halo-tagged wild-type or class-1 mutant variants of FOXA1. Transfected cells were seeded in glass-bottomed DeltaT culture dishes (Bioptechs; cat. no. 04200417C) and incubated for 24 h with 0.01 μg/ml of doxycycline. Cells were then treated with phenol-red-free medium containing 2% FBS and 5 nM cell permeable JF549 Halo ligand dye 33 for 30 min at 37 °C. Cells were subsequently washed twice, 10 min per wash at 37 °C, with phenol-red-free medium containing 2% FBS. Before imaging, cells were washed once with the 1× HBSS buffer and were imaged in the buffer.
Single particle tracking was performed on an Olympus IX81 microscope via HILO illumination, as previously described 34 , at a spatial accuracy of 30 nm and temporal resolution of 33 ms. Image analysis was performed as previously described 35 . In brief, tracking was done in Imaris (bitplane) and particles that were at least visible for four continuous frames were used for further analysis. Diffusion constants were calculated as previously described 36 , assuming a Brownian diffusion model under steady-state conditions. Dwell time histograms were fit to a doubleexponential function to extract fast and slow dwell times of 'bound' particles that displayed a frame-to-frame displacement of <300 nm. All particles that were visible for less than 4 consecutive frames, or those that moved >300 nm between frames, were counted as 'unbound' particles. At least 5 cells were imaged for each transcription factor variant and >500 particles were tracked to extract diffusion constants and dwell time. Dual luciferase AR reporter assay. HEK293 cells stably overexpressing the wild-type AR protein (that is, HEK293-AR) were used for the AR reporter assays. HEK293-AR cells were seeded in a 12-well plate at 300,000 cells per well and transfected with 2 μg of the pLenti6/V5 vector encoding different variants of FOXA1, or GFP (control). After 8 h, medium was replaced with 10% CSS-supplemented phenol-free medium (androgen-depleted) and cells were transfected with the AR reporter Firefly luciferase or negative-control constructs from the Cignal AR-Reporter(luc) kit (Qiagen; cat. no. CCS-1019L) as per the manufacturer's instructions. Both constructs were premixed with constitutive Renilla luciferase vector as control. After 12 h, cells were treated with different dosages of DHT or enzalutamide (at 10 μM dosage); and additional 24 h later dual luciferase activity was recorded for every sample using the Dual-Glo Luciferase assay (Promega; E2980) and luminescence plate reader (Promega-GLOMAX-Multi Detection System). Each treatment condition had four independent replicates. Firefly luciferase signals were normalized with the matched Renilla luciferase signals to control for variable cell number and/or transfection efficiencies, and normalized signals were plotted relative to the negative control reporter constructs. Electrophoretic mobility shift assay. HEK293 cells were plated in 10-cm dishes at 1 million per plate and transfected with 10 μg of the pLenti6/V5 vector coding GFP (control) or different variants of FOXA1. After 48 h, cells were trypsinized and nuclear lysates were prepared using the NE-PER kit reagents (Thermo Fisher Scientific). Immunoblots were run to confirm comparable expression of recombinant FOXA1 variants in 2 μl (that is, equal volume) of final nuclear lysates. Next, FOXA1 and AR ChIP-seq data were used to identify the KLK3 enhancer element. Sixty base pairs of the KLK3 enhancer, centred at the FOXA1 consensus motif 5′-GTAAACAA-3′, were synthesized as single-stranded oligonucleotides (IDT) and biotin-labelled using the Biotin 3′-End DNA labelling kit (Thermo Fisher Scientific), and then annealed to generate a labelled double-stranded DNA duplex.
Binding reactions were carried out in 20-μl volumes containing 2 μl of the nuclear lysates, 50 ng/μl poly(dI.dC), 1.25% glycerol, 0.025% Nonidet P-40 and 5 mM MgCl 2 . Biotin-labelled KLK3 enhancer probe (10 fmol) was added at the very end with gentle mixing. Reactions were incubated for 1 h at room temperature, size-separated on a 6% DNA retardation gel (100 V for 1 h; Invitrogen) in 0.5× TBE buffer, and transferred on the Biodyne Nylon membrane (0.45 μm; Thermo Fisher Scientific) using a semi-dry system (BioRad). Transferred DNA was crosslinked to the membrane using the UV light at 120 mJ/cm 2 for 1 min. Biotin-labelled free and protein-bound DNA was detected using HRP-conjugated streptavidin (Thermo Fisher Scientific) and developed using chemiluminescence according to the manufacturer's protocol. Protein synthesis and purification. First, wild-type FOXA1 and FOXA1(P358fs) proteins were purified using the Escherichia coli bacterial expression system and nickel-affinity chromatography. In brief, wild-type FOXA1 or FOXA1(P358fs) coding sequences were cloned into the pFC7A (HQ) Flexi vector (Promega; cat. no. C8531) with a C-terminal HQ tag, following the manufacturer's protocol. These expression constructs were used to transform Single Step (KRX) Competent E. coli cells (Promega; cat. no. L3002), which have been modified for synthesis of mammalian proteins. A starter broth of 2 ml was inoculated with a single colony of transformed bacterial cells and incubated at 37 °C with constant shaking at 250 rpm until an optical density at 600 nm (OD 600 ) of 0.4-0.5 was reached. The starter brother was then used to inoculate 1,000 ml of LB broth containing ampicillin, and protein synthesis was induced using 0.1% v/v of rhamanose. Induced culture was incubated at 20 °C for 16 h with constant shaking at 250 rpm. Bacterial cells were then pelleted by centrifugation at 4,000 rpm for 30 min and mechanically lysed through sonication in 50 mM Tris (pH 7.4), 150 mM NaCl, 1 mM MgCl 2 , 0.5 mM EDTA, 1 mM DTT and 1% glycerol in the presence of protease inhibitors (Roche). HisLink Purification Resin (Promega; cat. no. V8821) was used to purify untagged recombinant proteins from the crude bacterial lysates as per the manufacturer's protocol (this also includes removal of the His tag). Purified protein fractions were then tested for purity by Coomaisse staining relative to the crude input lysates, and purified protein concentrations were estimated using protein standards of known concentrations (Thermo Fisher Scientific; cat. no. 23208). The identities of purified proteins were confirmed via immunoblotting using an N-terminal FOXA1 antibody (Cell Signaling Technology; cat. no. 58613S). Biolayer interferometry assay. Biolayer interferometry (BLI) assays were carried out using the Octet-RED96 system (PALL ForteBio) and in-built analysis software. In brief, a biotin-labelled, 60-bp KLK3 enhancer element centred at the FOXA1 consensus motif was immobilized on the Super Streptavidin Biosensors (PALL ForteBio, part no. 18-5057) with the loading step carried out for 1,000 s with shaking at 500 rpm. This was followed by baseline measurements for 120 s and association for 900 s using varying concentrations of purified FOXA1 proteins (3.125-100 nM; two replicate biosensors per concentration). A control DNA element with no FOXA1 motif was used in the negative-control reaction with 100 nM of the protein. The association step was followed by the dissociation step for 3,000 s. Signal from all the biosensors was adjusted for the background signal from the control sensors and normalized data of DNA binding kinetics were analysed using the Octet-RED96 (PALL ForteBio) analysis software, as previously described 37 . Generation of CRISPR clones and stable lines. 22RV1 or LNCaP cells were seeded in a 6-well plate at 200,000 cells per well and transiently transfected with 2.5 μg of lentiCRISPR-V2 (Addgene; 52961) vector using the Lipofectamine 3000 reagent (cat. no. L3000008), encoding the Cas9 protein and sgRNA that cuts either at amino acid 271 (5′-GTCAAGTGCGAGAAGCAGCCG-3′) or 359 (5′-GCCGGGCCCGGAGCTTATGGG-3′) in exon 2 of FOXA1. Cells were treated with non-targeting control sgRNA (5′-GACCGGAACGATCTCGCGTA-3′) vector to generate isogenic wild-type clones. Transfected cells were selected with puromycin (Gibco) for 3-4 days and sorted by fluorescence-activated cell sorting as single cells into 96-well plates. Cells were maintained in 96-well plates for 4-6 weeks, with replacement of the growth medium every 7 days to allow for the expansion of clonal lines. Clones that successfully seeded were further expanded and genotyped for FOXA1 using Sanger sequencing, and immunoblotting with the N-terminal FOXA1 antibody. Sequence-and expression-validated 22RV1 and LNCaP clones with distinct class-2 mutations were used for growth, invasion and metastasis assays as described.
To generate stable cells, doxycycline-inducible vectors coding different variants of FOXA1 or GFP (control) were packaged into viral particles at the University of Michigan Vector Core. Prostate cancer cells were seeded in a 6-well plate at 100,000-250,000 cells per well and infected with 0.5 ml of 10× viral titres packaged at the University of Michigan Vector Core. This was followed by 3-4 days of puromycin (Gibco) selection to generate stable lines. Rescue growth and functional compensation experiments. Stable 22RV1 cells with doxycycline-inducible expression of empty vector (control), FOXA1 wild type, or distinct FOXA1 mutants were seeded in a 6-well plate in the completed growth medium supplemented with 1.0 μg/ml of doxycycline. Notably, the exogenous genes only contain the coding sequence of FOXA1 without its intron and UTRs. After 24 h, cells were transfected with 30 nM of either distinct 3′ UTR-specific FOXA1-targeting siRNAs or a non-targeting control siRNA using the RNAiMAX (Life Technologies; cat. no. 13778075) reagent. FOXA1 UTR-specific siRNAs were purchased from Thermo Fisher Scientific (cat. no. siNC, 4390844 (sequence is proprietary); siRNA no. 3, s6687 (sense sequence: 5′-GCAAUACUCUUAACCAU AA-3′); siRNA no. 4, 5278 (sense sequence: 5′-AACACATAAAATTAGTTTC-3′); and siRNA no. 5 -107428 (sense sequence: 5′-AAGTTATAGGGAGCTGGAT-3′)). On the following day, cells were counted and seeded in a 96-well plate at a density of 5,000 cells per well with 6 replicates for each treatment condition. Cell growth was then assessed using the IncuCyte assay, as described above. Testing the GFP-tagged wild-type FOXA1 variant. 22RV1 cells were seeded in 10-cm dishes and transfected with 8 μg of mammalian expression plasmids encoding either FOXA1(WT) or FOXA1(WT)-GFP (the exact construct used in the FRAP assay) using the Lipofectamine 3000 (Life Technologies; cat. no. L3000008) reagent, as per the manufacturer's protocol. Transgene expression was induced using 1.0 μg/ml of doxycycline and cells were cultured for 96 h with doxycycline replenishment every 48 h. Total RNA was extracted and RNA-seq was performed as described. A portion of these cells was used for the rescue growth experiments using UTR-specific FOXA1 siRNAs as described above.
Matrigel invasion assay. 22RV1 CRISPR clones were grown in 10% CSSsupplemented medium for 48 h for androgen starvation. A matrigel-coated invasion chamber was used, which was additionally coated with a light-tight polyethylene terephthalate membrane to allow for fluorescent quantification of the invaded cells (Biocoat: 24-well format, no. 354166). Fifty thousand starved cells were resuspended in serum-free medium and were added to each invasion chamber. Twenty per cent FBS-supplemented medium was added to the bottom wells to serve as a chemoattractant. After 12 h, medium from the bottom well was aspirated and replaced with 2 μg/ml Calcein-green AM dye (Thermo Fisher Scientific; C3100MP) in 1× HBSS (Gibco) and incubated for 30 min at 37 °C. Invasion chambers were then placed in a fluorescent plate reader (Tecan-Infinite M1000 PRO) and fluorescent signals from the invaded cells at the bottom were averaged across 16 distinct regions per chamber to determine the extent of invasion. ChIP-seq. ChIP experiments were carried out using the HighCell# ChIP-Protein G kit (Diagenode) as per the manufacturer's protocol. Chromatin from five million cells was used per ChIP reaction with 6.5 μg of the target protein antibody. In brief, cells were trypsinized and washed twice with 1× PBS, followed by crosslinking for 8 min in 1% formaldehyde solution. Crosslinking was terminated by the addition of 1/10 volume 1.25 M glycine for 5 min at room temperature followed by cell lysis and sonication (Bioruptor, Diagenode), resulting in an average chromatin fragment size of 200 bp. Fragmented chromatin was then used for immunoprecipitation using various antibodies, with overnight incubation at 4 °C. ChIP DNA was de-crosslinked and purified using the iPure Kit V2 (Diagenode) using the standard protocol. Purified DNA was then prepared for sequencing as per the manufacturer's instructions (Illumina). ChIP samples (1-10 ng) were converted to blunt-ended fragments using T4 DNA polymerase, E. coli DNA polymerase I large fragment (Klenow polymerase) and T4 polynucleotide kinase (New England BioLabs (NEB)). A single A base was added to fragment ends by Klenow fragment (3′ to 5′ exo minus; NEB) followed by ligation of Illumina adaptors (Quick ligase, NEB). The adaptor-ligated DNA fragments were enriched by PCR using the Illumina Barcode primers and Phusion DNA polymerase (NEB). PCR products were size-selected using 3% NuSieve agarose gels (Lonza) followed by gel extraction using QIAEX II reagents (Qiagen). Libraries were quantified and quality checked using the Bioanalyzer 2100 (Agilent) and sequenced on the Illumina HiSeq 2500 Sequencer (125-nucleotide read length). Zebrafish embryo metastasis experiment. Wild-type AB TL zebrafish were maintained in aquaria according to standard protocols. Embryos were generated by natural pairwise mating and raised at 28.5 °C on a 14 h light/10 h dark cycle in a 100-mm Petri dish containing aquarium water with methylene blue to prevent fungal growth. All experiments were performed with 2-7-day-old embryos post-fertilization, and were done in approved University of Michigan fish facilities using protocols approved from the University of Michigan Institutional Animal Care and Use Committee (UM-IACUC). Cell injections were carried out as previously described 38 . In brief, GFP-expressing normal (control) or cancer cells were resuspended in PBS at the concentration of 1 × 10 7 cells/ml. Forty-eight hours after fertilization, wild-type embryos were dechorionated and anaesthetized with 0.04 mg/ml tricaine. Approximately 10 nl (approximately 100 cancer cells) were microinjected into the perivitelline space using a borosilliac micropipette tip with filament. Embryos were returned to aquarium water and washed twice to remove tricaine, then moved to a 96-well plate with one embryo per well and kept at 35 °C for the duration of the experiment. All embryos were imaged at 24-h intervals to follow metastatic dissemination of injection cells. Water was changed daily to fresh aquarium water. More than 30 fish were injected for each condition (wild-type no. 2, n = 30; wild-type no. 5, n = 50; no. 57, n = 35; no. 84, n = 57; no. 113, n = 38) and metastasis was visually assessed daily up to 5 days after injection (that is, for a total of 7 days post-fertilization) by counting the total number of distinct cellular foci in the body of the embryos. All of the metastasis studies were terminated at seven days post-fertilization in accordance with the approved embryo protocols. Embryos were either imaged directly in the 96-well plates or placed onto a concave glass slide to capture representative images using a fluorescent microscope (Olympus-IX71). For quantification, evidently distinct cell foci in the embryo body were counted 72 h after the injections.
For all these experiments, relevant ethical regulations were carefully followed. No statistical methods were used to predetermine sample size for any of the cohort analyses or experiments. The experiments were not randomized and investigators were not blinded to allocation during experiments and outcome assessment unless otherwise stated. ATAC-seq and data analysis. ATAC-seq was performed as previously described 39 . In brief, 25,000 normal prostate or prostate cancer cells were washed in cold PBS and resuspended in cytoplasmic lysis buffer (CER-I from the NE-PER kit, Invitrogen, cat. no. 78833). This single-cell suspension was incubated on ice for 10 min with gentle mixing by pipetting at every 2 min. The lysate was centrifuged at 1,300g for 5 min at 4 °C. Nuclei were resuspended in 2× TD buffer, then incubated with Tn5 enzyme for 30 min at 37 °C (Nextera DNA Library Preparation Kit;
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cat. no. FC-121-1031). Samples were immediately purified by Qiagen minElute column and PCR-amplified with the NEBNext High-Fidelity 2X PCR Master Mix (NEB; cat. no. M0541L). qPCR was used to determine the optimal PCR cycles to prevent over-amplification. The amplified library was further purified by Qiagen minElute column and SPRI beads (Beckman Coulter; cat. no. A63881). ATAC-seq libraries were sequenced on the Illumina HiSeq 2500 (125-nucleotide read length).
Paired-end .fastq files were uniquely aligned to the hg38 human genome assembly using Novoalign (Novocraft) (with the parameters -r None -k -q 13 -k -t 60 -o sam -a CTGTCTCTTATACACATCT), and converted to .bam files using SAMtools (version 1.3.1). Reads mapped to mitochondrial or duplicated reads were removed by SAMtools and PICARD MarkDuplicates (version 2.9.0), respectively. Filtered .bam files from replicates were merged for downstream analysis. MACS2 (2.1.1.20160309) was used to call ATAC-seq peaks. The coverage tracks were generated using the program bam2wig (http://search.cpan.org/dist/Bio-ToolBox/) with the following parameters:-pe-rpm-span-bw. Bigwig files were then visualized using the IGV (Broad Institute) open source genome browser. ChIP-seq data analysis. Paired-end 125-bp reads were trimmed and aligned to the GRCh38 human reference using the STAR (version 2.4.0g1) aligner with splicing disabled; the resulting reads were filtered using samtools 'samtools view -@ 8 -S -1 -F 384' . The resulting .bam file was sorted and duplicate-marked using Novosort, and converted into a bigwig file for visualization using 'bedtools genomecov -bg -split -ibam' and 'bedGraphToBigWig' . The coverage signal was normalized to total sequencing depth/1 × 10 6 reads. Peak calling was performed using MACS2 with the following settings: 'macs2 callpeak-call-summits-verbose 3 -g hs -f BAM -n OUT-qvalue 0.05' . ChIP peak profile plots and read-density heat maps were generated using deepTools2 40 , and cistrome overlap analyses were carried out using the ChIPpeakAnno 41 package in R. It is important to note that, given the cistromic dominance of class-2 mutants, in heterozygous class-2 mutant clones part of the FOXA1 antibody binds to the wild-type protein that does not interact with, or immunoprecipitate, the DNA. This confounds all analyses involving peak-read density comparisons between the wild-type and class-2-mutant FOXA1 ChIP-seq data; we therefore largely avoided this strategy in our study. For the same reason, the read densities from only the heterozygous clones were factored by 1.5 for heat map generation in Fig. 3d . De novo and known motif enrichment analysis. All de novo and known motif enrichment analyses were performed using the HOMER (v.4.10) suite of algorithms 42 . Peaks were called by the findPeaks function (-style factor -o auto) at 0.1% false discovery rate; de novo motif discovery and enrichment analysis of known motifs were performed with findMotifsGenome.pl (-size 200 -mask). For motif analysis of common wild-type-and mutant-specific chromatin binding sites, the top 5,000 peaks ranked by score were used as input. A common set of background sequences was generated by di-nucleotide shuffling of the input sequences using the fasta-shuffle-letters function from MEME 43 . Alternatively, we ranked peaks by the relative signal fold change between mutant and wild type, and selected the top and bottom 5,000 peaks (keeping the requirement that mutant-specific peaks are not called in the wild-type cistrome, and vice versa) for motif discovery. For class-2 mutants, only heterozygous 22RV1 clones were used, which more accurately recapitulate the clinical presentation of FOXA1 mutations. Also, for both mutational classes, cistromes from biological replicates were merged to define a union cistrome that was compared to the union wild-type cistrome generated from matched FOXA1 wild-type cells. For the supervised motif analyses, we identified all instances of the FOXA canonical motif (5′-T[G/A]TT[T/G]AC-3′) within cistromes (ChIP-seq peaks) of class-1 and wild-type FOXA1 proteins using motifmatchR, and calculated nucleotide frequencies in the flanking positions. Cohorts, datasets and resources. This study uses previously published public or restricted patient genetic data. Genetic calls for primary prostate cancer and breast cancer were obtained from the Genomic Data Commons (GDC) 44 for the prostate cancer PRAD 5 and breast cancer BRCA 6,45 cohorts, respectively. Raw RNA-seq data (paired-end reads from unstranded polyA libraries) for the samples were downloaded from the GDC and processed with our standard clinical RNA-seq pipeline CRISPR/CODAC (see below). For The Cancer Genome Atlas (TCGA) PRAD and BRCA cohorts, we downloaded mutational calls from multiple sources (GDC, cBio Portal and UCSC Xena) and additionally used the BAM-slicing tool to download sequence alignments from whole-exome sequencing libraries to the FOXA1 locus. We then used our internal pipeline (see below) to call single-nucleotide variants and indels within FOXA1. We also used the downloaded aligned data for manual review of FOXA1 mutation calls. Mutation calls for advanced primary and metastatic cases were obtained from the MSK-IMPACT cohort (downloaded from the cBio portal 46 ). The main MCTP mCRPC cohort includes 360 previously reported cases (the location of all raw .bam files is provided in ref. 47 ), the 10 additional mCRPC cases included here (but not in ref. 47 ) will be included in the Database of Genotypes and Phenotypes (dbGaP) under accession code phs000673.v3.p1, and belong to a continuous sequencing program with the same IRB-approved protocol (MI-Oncoseq program, University of Michigan Clinical Sequencing Exploratory Research). The genetic sequencing data (WXS) for rapid autopsy cases are available from dbGaP with accession codes hs000554.v1.p1and phs000567. v1.p1. De-identified somatic mutation calls, RNA-seq fusion calls, processed and segmented copy-number data, and RNA-seq expression matrices across the full 370 cases of the MCTP mCRPC cohort are available on request from the authors. Preparation of whole-exome sequencing and RNA-seq libraries. Integrative clinical sequencing (comprising exome sequencing and polyA and/or capture RNA-seq) was performed using standard protocols in our Clinical Laboratory Improvement Amendments-compliant sequencing laboratory. In brief, tumour genomic DNA and total RNA were purified from the same sample using the AllPrep DNA/RNA/miRNA kit (Qiagen). Matched normal genomic DNA from blood, buccal swab or saliva was isolated using the DNeasy Blood & Tissue Kit (Qiagen). RNA-seq was performed using the exome-capture transcriptome platform 48 . Exome libraries of matched pairs of tumour and normal DNA were prepared as previously described 49 , using the Agilent SureSelect Human All Exon v4 platform (Agilent). All the samples were sequenced on an Illumina HiSeq 2000 or HiSeq 2500 (Illumina) in paired-end mode. The primary base call files were converted into FASTQ sequence files using the bcl2fastq converter tool bcl2fastq-1.8.4 in the CASAVA 1.8 pipeline. Analysis of whole-exome sequencing data. The .fastq sequence files from whole-exome libraries were processed through an in-house pipeline constructed for analysis of paired tumour and normal data. The sequencing reads were aligned to the GRCh37 reference genome using Novoalign (version 3.02.08) (Novocraft) and converted into .bam files using SAMtools (version 0.1.19). Sorting, indexing, and duplicate marking of .bam files used Novosort (version 1.03.02). Mutation analysis was performed using freebayes (version 1.0.1) and pindel (version 0.2.5b9). Variants were annotated to RefSeq (via the UCSC genome browser, retrieved on 22 August 2016), as well as COSMIC v.79, dbSNP v.146, ExAC v.0.3 and 1000 Genomes phase 3 databases using snpEff and snpSift (v.4.1g). Single nucleotide variants and indels were called as somatic if they were present with at least 6 variant reads and 5% allelic fraction in the tumour sample, and present at no more than 2% allelic fraction in the normal sample with at least 20× coverage. Additionally, the ratio of variant allelic fractions between tumour and normal samples was required to be at least six to avoid sequencing and alignment artefacts at low allelic fractions. Minimum thresholds were increased for indels observed to be recurrent across a pool of hundreds of platform-and protocol-matched normal samples. Specifically, for each such indel, a logistic regression model was used to model variant and total read counts across the normal pool using PCR duplication rate as a covariate, and the results of this model were used to estimate a predicted number of variant reads (and therefore allelic fraction) for this indel in the sample of interest, treating the total observed coverage at this genomic position as fixed. The variant read count and allelic fraction thresholds were increased by these respective predicted values. This filter eliminates most recurrent indel artefacts without affecting our ability to detect variants in homopolymer regions from tumours exhibiting microsatellite instability. Germline variants were called using 10 variant reads and 20% allelic fraction as minimum thresholds, and were classified as rare if they had less than 1% observed population frequency in both the 1000 Genomes and ExAC databases. Exome data were analysed for copy-number aberrations and loss of heterozygosity by jointly segmenting B-allele frequencies and log 2 -transformed tumour/normal coverage ratios across targeted regions using the DNAcopy (version 1.48.0) implementation of the Circular Binary Segmentation algorithm. The expectationmaximization algorithm was used to jointly estimate tumour purity and classify regions by copy-number status. Additive adjustments were made to the log 2 -transformed coverage ratios to allow for the possibility of non-diploid tumour genomes; the adjustment resulting in the best fit to the data using minimum mean-squared error was chosen automatically and manually overridden if necessary. Detection of copy-number break ends from whole-exome sequencing. The output of our clinical whole-exome sequencing pipeline includes segmented copy-number data, inferred absolute copy numbers and predicted parent-specific genotypes (for example, AAB), detection of loss of heterozygosity, and detection of copy-neutral loss of heterozygosity (uniparental disomy). Together, these data enable the detection of joint discontinuities in the copy-number profile (log-ratio and B-allele frequencies) at exon-level resolution. A subset of genomic rearrangements results in changes in copy number or allelic shifts, and the presence of such discontinuities in paired tumour-normal whole-exome sequencing data are therefore strongly indicative of a somatic breakpoint. For example, one copy gain will result in a segment with an increased log-ratio, and a corresponding zygosity deviation (see above). This segment will be discontinuous with adjacent segments, which will result in the call of a whole-exome sequencing break end (discontinuity) on either side of the copy gain. The size of the break end depends on the density of covered exons and in general the resolution is better in genic versus intergenic regions. We assessed the presence of such breakpoints within the gene-dense and exon-dense FOXA1 locus; all copy-number break ends met statistical thresholds of the circular binary segmentation (CBS) algorithm (see above) at either the log-ratio or B-allele level.
Genetic characterization of mCRPC tumour samples at the pathway level. The co-occurrence or mutual exclusivity of FOXA1 alterations with other previously described genetic events in prostate cancer has been carried out at the pathway level, but grouping putative functionally equivalent (and largely genetically mutually exclusive) events. All known types of ETS fusion (ERG, ETV1, FLI1, ETV4 and ETV5) were considered as ETS-positive tumours, PI3K alterations included PTEN homozygous loss, PIK3CA activating mutations and PIK3R1 inactivating mutations, AR pathway alterations included AR, NCOR1, NCOR2 and ZBTB16 mutations or deletions, but excluded AR amplifications and copy gains. The KMT category included mutations in all recurrently mutated lysine methyltransferases. The WNT category included inactivating alterations in APC and activating mutations in CTNNB1. DRD included cases with mutations in BRCA1, BRCA2, PALB2 and ATM (all common mismatch repair genes), and CDK12. Assessment of two-hit biallelic alterations. To assess the frequency of genetic inactivations of both alleles we integrated mutational, copy-number and RNA-seq (fusion) data. A gene was considered as having both alleles inactivated for any combination (pair) of the following events: copy loss, mutation, truncating fusion and copy-number breakpoint, in addition to homozygous deletion of both copies and two independent mutations. Ambiguous cases were manually reviewed to increase the accuracy and ascertain whether both events, for example, copy-number breakpoint and gene fusion, are probably independent events. Unified mutation calling and variant classification of FOXA1. Mutation calls for FOXA1 obtained or downloaded from the GDC and TCGA flagship manuscripts 5, 6 as well as our internal pipelines were lifted over to GRCh38 (using the Bioconductor package rtracklayer) and annotated with respect to the canonical RefSeq FOXA1 isoform. For TCGA samples or cases, multiple call sets were available and we manually reviewed all discrepancies in FOXA1 mutation calls, resulting in a unified call set with improved sensitivity and specificity. Mutational effect (consequence) was simplified into three categories: missense, in-frame indel and frameshift (the last category included stop-gain, stop-loss and splice-site mutations). The resulting mutations were dichotomized into class 1 and class 2 based on their position relative to amino acid residue 275. Variant allele frequencies were only available for TCGA and the in-house mCRPC cohorts. Analysis of whole-genome sequencing data. The bcbio-nextgen pipeline version 1.0.3 was used for the initial steps of tumour whole-genome data analysis. Paired-end reads were aligned to the GRCh38 reference using BWA (bcbio default settings), and structural variant calling was done using LUMPY 50 (bcbio default settings), with the following post-filtering criteria:
The following settings were chosen to minimize the number of expected germline variants: false discovery rate (FDR) < 0.05 for germline status for both deletions and duplications. Additionally, common structural germline variants were filtered. Analysis of 10X genomics long-read sequencing data. High-molecular mass DNA from MDA-PCA-2b and LNCaP cell lines was isolated and processed into linked-read next-generation sequencing libraries per the manufacturer's instructions (10X WGS v2 kit). The resulting paired-end sequencing data were sequenced on an Illumina Hi-Seq 2500 instrument and analysed (demultiplexing, alignment, phasing and structural variant calls) using the longranger 2.2.1 pipeline with all default settings. The resulting libraries met all 10X-recommended quality control parameters including molecule size, average phasing length, and sequencing coverage (~50×). Here, we focused on structural variant calls within the FOXA1 TAD and confirmed the presence of the previously reported FOXMIND-ETV1 fusions; that is, translocation for MDA-PCA-2b, and balanced insertional translocation for LNCaP. Both cell lines were confirmed to contain three copies of FOXA1 (that is, one translocated allele and two duplicated alleles). RNA-seq data pre-processing and primary analysis. RNA-seq data processingincluding quality control, read trimming, alignment, and expression quantification by read counting-was carried out as previously described 49 , using our standard clinical RNA-seq pipeline CRISP (available at https://github.com/mcieslik-mctp/ bootstrap-rnascape). The pipeline was run with default settings for paired-end RNAseq data of at least 75 bp. The only changes were made for unstranded transcriptome libraries sequenced at the Broad Institute and the TCGA and CCLE cohorts, for which quantification using featureCounts 51 was used in unstranded mode '-s0' . The resulting counts were transformed into fragments per kilobase of transcript per million mapped reads using upper-quartile normalizations as implement ed in EdgeR 52 . For mCRPC samples FOXA1 expression estimates were adj usted by tumour content estimated from whole-exome sequencing (see above) given the highly prostate-specific FOXA1 expression profile. For the quantification of FOXMIND expression levels, a custom approach was necessary given the poor annotation and unspliced nature of this transcript. First, we delineated regions of sense and antisense transcription from the FOXMIND ultra-conserved regulatory elements, chr14:37564150-37591250:+ and chr14:37547900-37567150:-, respectively. Next, to make the expression estimates reliable in unstranded libraries, we identified regions of substantial overlap between the sense and antisense RP11-356O9.1 transcripts, and FOXA1 and MIPOL1. These overlaps have been excluded from quantification, resulting in the following trimmed target regions: chr14:37564150-37589500, and chr14:37553500-37567150. Within these regions, the average base-level coverage normalized to sequencing depth was computed as an expression estimate. Differential expression analyses. All differential expression analyses were done using limma R-package 53 , with the default settings for the voom 54 , lmFit, eBayes and topTable functions. The contrasts were designed as follows to identify transcriptional signatures of class-1 mutants. Given the mutual exclusivity of the genotypes in primary and metastatic tumours, the overall MCTP mCRPC cohort of 371 cases was partitioned into 4 groups: (1) ETS-fused or SPOP-mutant tumours, (2) class-1 mutant tumours, (3) class-2 mutant tumours, and (4) tumours that were wild type for ETS, SPOP and FOXA1. To avoid confounding effects, the class-2 and ETS and SPOP groups were excluded from class-1 transcriptional analyses. Next, the class-1 samples were contrasted with the wild-type samples with additional independent regressors for assay type (capture vs polyA, as previously described 49 , and mutational status (see above) for the following genes and pathways: PI3K, WNT, DRD, RB1 and TP53. In other words, we constructed a design matrix with coefficients for class-1 mutational status, in addition to coefficients for confounding variables and recurrent genetic heterogeneity. This allowed us to estimate the fold changes (expressed logarithmically) and adjusted P values associated with FOXA1 mutations and other genotypes (for example, PI3K status). An analogous procedure was carried out for the primary class-1 samples (TCGA) and for class-2 mutations in mCRPC (MCTP), but given the lack of mutual-exclusivity between class-2 mutations and ETS and SPOP group, only class-1 mutations were excluded. Pathway and signature enrichment analyses. The Molecular Signatures Database (MSigDB) 55 was used as a source of gene sets comprising cancer hallmarks, molecular pathways, oncogenic signatures and transcription factor targets. The enrichment of signatures was assessed using the parametric random-set method 56 , and visualized using the gene-set enrichment analysis (GSEA) enrichment statistic 57 and barcode plots. All P values have been adjusted for multiple-hypothesis testing using a false discovery rate correction. To identify putative transcription factors regulating differentially expressed genes, we used the transcription factor prediction tool BART 25 . BART was run with all default settings, and the provided transcription factor databases. We used voom-and limma-based gene-level fold-changes as input to the algorithm. Detection of structural variants from RNA-seq. The detection of chimeric RNAs (gene fusions, structural variants, circular RNAs and read-through events) was carried out using our previously published 49 in-house toolkit for the comprehensive detection of chimeric RNAs, CODAC (available at https://github.com/ mctp/codac). In brief, three separate alignment passes (STAR 2.4.0g1) against the GRCh38 (hg38) reference with known splice junctions provided by Gencode v.27 (ref. 58 ) are made for the purposes of expression quantification and fusion discovery. The first pass is a standard paired-end alignment followed by gene-expression quantification. The second and third pass are for the purpose of gene fusion discovery and to enable the chimeric alignment mode of STAR (chimSegmentMin: 10, chimJunctionOverhangMin: 1, alignIntronMax: 150000, chimScoreMin: 1). Fusion detection was carried out using CODAC with default parameters to balance sensitivity and specificity (annotation preset:balanced). CODAC uses MOTR v.2, a custom reference transcriptome based on a subset of Gencode 27 (available with CODAC). Prediction of topology (inversion, duplication, deletion and translocation), and distance (adjacent, breakpoints in two directly adjacent loci; cytoband, breakpoints within the same cytoband based on UCSC genome browser; arm, breakpoints within the same chromosome arm). The high specificity of our pipeline has been assessed through Sanger sequencing 49 . To create fusion circos plots, we have colour-coded the CODAC variants on the basis of the inferred topology of the breakpoints. Unbiased discovery of recurrently rearranged loci has been carried out by breaking the genome into 1.5-Mb windows with a step of 0.5 Mb. For each window, the percentage of patients with at least one RNA break end has been calculated. The resulting genomic windows were ranked and clustered by proximity for visualization. CODAC has the ability to make fusion calls independent of known transcriptome references or annotations and is therefore capable of detecting fusions involving intergenic or poorly annotated regions. Classification of FOXA1 locus genomic rearrangements. Structural variants within the FOXA1 locus have been partitioned into two broad topological patterns: (1) translocations (including inversions and deletions involving distal loci on the same chromosome) and (2) focal duplications. The translocations have been further subdivided into hijacking and swapping events on the basis of their position relative to FOXMIND (GRCh38: chr14:37564150-37591250) and FOXA1. Hijacking translocations position a translocation partner within the FOXMIND-FOXA1 regulatory domain (defined as GRCh38: chr14:37547501-37592000, based on manual review of chromatin conformation Hi-C, CTCF, H3K4me1, H3K27ac, evolutionary conservation and synteny data). Swapping translocations preserve the FOXMIND-FOXA1 regulatory domain but insert the translocation partner upstream of the FOXA1 promoter, frequently 'swapping-out' the TTC6 gene. Notably, one isoform of TTC6 gene can be transcribed from the bi-directional FOXA1 promoter. Focal duplications within the FOXA1 locus have been derived from the CODAC structural-variant output file. In brief, for each case independently, all RNA-seq fusion junctions annotated by CODAC as tandem duplications and overlapping the FOXA1 topologically associating domain (GRCh38: chr14:37210001-37907919) have been collated and used to infer the minimal duplicated region. Because RNA-seq chimeric junctions generally coincide with splice junctions (limited resolution) and generally cannot be phased (ambiguous haplotype), the inference of minimal duplicated regions makes the necessary and parsimonious assumption that overlapping tandem duplications are due to a single somatic genetic event, and not multiple independent events. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
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Extended Data Fig. 1 | Functional essentiality and Supplementary Fig. 1 . g, Crystal-violet stain of AR − DU145 prostate cancer and LNCaP (control) cells treated with siNC, AR-or FOXA1-targeting siRNAs. Results represent 3 independent experiments (n = 2 biological replicates). h, Averaged proliferation z-scores for 6 independent FOXA1-targeting sgRNAs extracted from publically available CRISPR Project Achilles data (BROAD Institute) in prostate and breast cancer cells. HPRT1 and AR data serve as negative and positive controls, respectively. Mean ± s.e.m. is shown; dots are proliferative z-scores for independent sgRNAs. i, Ranked depletion or enrichment of sgRNA read counts from GeCKO-V2 CRISPR knockout screen in LNCaP cells (at day 30) relative to the input sample. Only a subset of genes-including essential controls, chromatin modifiers and transcription factors-is visualized. j, Recurrence of FOXA1 mutations across TCGA, MSK-IMPACT and SU2C cohorts. k, Density of break ends (RNA-seq chimeric junctions) within overlapping 1.5-Mb windows along chr14 in mCRPC tumours. l, Whole-genome sequencing (WGS) of seven mCRPC index cases with distinct patterns of FOXA1 translocations (Tlocs) and duplications (Dups), nominated by RNA-seq (WA46, WA37, WA57 and MO_1584) or whole-exome sequencing (MO_1778, SC_9221 and MO_1637). m, Concordance of RNA-seq (chimeric junctions) and whole-exome-sequencing-based FOXA1 locus rearrangements calls (mCRPC cohort). CNV, copy-number variation. n, Frequency of FOXA1 locus rearrangements in mCRPC based on RNA-seq and whole-exome sequencing.
Extended Data Fig. 2 | Genomic characteristics of the three classes  of FOXA1 alterations in prostate and breast cancer. a, b , Bi-allelic inactivation (a) and copy-number variations (b) of FOXA1 across mCRPC (n = 371). CN-LOH, copy-neutral loss of heterozygosity. c, FOXA1 expression (RNA-seq) in benign (n = 51), primary (n = 501) and metastatic (n = 535) prostate cancer. d, Distribution and functional categorization of FOXA1 mutations (all cases in the aggregate cohort) on the protein map of FOXA1. e, Aggregate and class-specific distribution of FOXA1 mutations in advanced breast cancer (MSK-IMPACT cohort). f, Structural classification of FOXA1 locus rearrangements in breast cancer (TCGA and CCLE cell lines). g, h, Variant allele frequency of FOXA1 mutations by tumour stage (g) and clonality estimates of class-1 and class-2 mutations (h) in tumour-content-corrected primary prostate cancer (n = 500) and mCRPC (n = 370) specimens. i, Mutual exclusivity or co-occurrence of FOXA1 mutations (two-sided Fisher's exact test). Mutations in AR, WNT, and PI3K were aggregated at the pathway level. ETS, ETS gene fusions; DRD, DNA repair defects and included alterations in BRCA1, BRCA2, ATM and CDK12; MMRD, mismatch repair deficiency (total n = 371). j, Mutual exclusivity of ETS and/or SPOP (n = 26) alterations with FOXA1 (n = 46) alterations distinguished by class in mCRPC (n = 371). k, Co-occurrence of WNT (n = 58) and DRD (n = 107) pathway alterations with FOXA1 alteration classes in mCRPC (n = 371). l, Stage-and class-specific increase in FOXA1 expression levels in primary (n = 500) and metastatic prostate cancer (n = 357). Left, two-sided t-test. Right, two-way ANOVA. For all box plots, centre shows median, box marks quartiles 1-3 and whiskers span quartiles 1-3 ± 1.5 × IQR. 
Extended Data Fig. 5 | DNA-binding dominance of the class-2 FOXA1  mutants. a, FOXA1 protein maps showing the recombinant proteins used to validate the N-terminal (N-term) and C-terminal (C-term) FOXA1 antibodies. b, Immunoblots depicting detection of all variants by the N-terminal antibody (left), and of only the full-length wild-type FOXA1 protein by the C-terminal antibody (right). These results were reproducible in two independent experiments. Antibody details are included in the Methods. c, Sanger sequencing chromatograms showing the heterozygous class-2 mutation in LAPC4 cells after the P358 codon in exon 2 (n = 2 technical replicates). All other tested prostate cancer cell lines were wild type for FOXA1. d, Immunoblots confirming the expression of the truncated FOXA1 variant in LAPC4 at the expected approximately 40-kDa size (top, red arrow). The short band is detectable only with the N-terminal (top) FOXA1 antibody and not the C-terminal (bottom) antibody. These results were reproducible in two independent experiments. e, Co-immunoprecipitation and immunoblotting of FOXA1 using N-terminal and C-terminal antibodies from LAPC4 nuclei with species-matched IgG used as control. f, Nuclear co-immunoprecipitation of FOXA1 from LAPC4 or LNCaP cells stimulated with DHT (10 nM for 16 h) using N-terminal and C-terminal antibodies. Species-matched IgG are controls. Immunoprecipitations and immunoblots in d-f were reproducible in two and three independent experiments, respectively. 
